Statistics for A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis

Total visits

views
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis 282

Total visits per month

views
January 2024 0
February 2024 0
March 2024 3
April 2024 30
May 2024 25
June 2024 30
July 2024 3

File Visits

views
burosumab-an-anti-fgf23-in-adults-with-x-linked-hypophosphatemia-week-24-primary.pdf 320

Top country views

views
United States 165
China 11
Germany 10
Spain 9
Canada 8
United Kingdom 8
Thailand 5
Ukraine 5
Colombia 4
Norway 4
Denmark 3
Croatia 3
Italy 3
Sweden 3
Brazil 2
South Korea 2
Mexico 2
Russia 2
Australia 1
Malaysia 1
New Zealand 1
Turkey 1
Uganda 1

Top city views

views
Wilmington 49
Fairfield 34
Houston 7
Jacksonville 6
Lake Mary 6
Bangkok 5
Kiev 5
Madrid 5
Toronto 5
Bogotá 4
Cambridge 4
Chicago 4
Osaka 4
Tokyo 4
Beijing 3
Kiez 3
New York 3
Oslo 3
San Diego 3
San Francisco 3
Zagreb 3
Bad Homburg 2
Baltimore 2
Chelmsford 2
Copenhagen 2
Landstuhl 2
London 2
Pamplona 2
Plantation 2
Québec 2
Shanghai 2
Albany 1
Ann Arbor 1
Bergen 1
Brasília 1
Brooklyn 1
Cesano Maderno 1
Coronado 1
Goiânia 1
Greve 1
Gunzenhausen 1
Harrow 1
High Wycombe 1
Hwaseong-si 1
Hässleholm 1
Kampala 1
Livorno 1
Malden 1
Manchester 1
Minneapolis 1
Munich 1
Old Saybrook 1
Ottawa 1
Providence 1
Reynosa 1
Saint Petersburg 1
San Giuliano Terme 1
Scottsdale 1
Seremban 1
Setagaya-ku 1
Stockholm 1
Stuttgart 1
Sydney 1
Terrassa 1
Uppsala 1
Valencia 1
Voorhees Township 1
Washington 1
White Plains 1
Zheleznogorsk 1